Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18573688 | 1.00 | CES2 (0.42) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL13543609 | 1.00 | CES2 (0.42) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL3427267 | 1.00 | CES2 (0.42) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL18214886 | 1.00 | CES2 (0.42) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL1341780 | 0.98 | CES2 (0.39) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL1340689 | 0.93 | RIPK1 (0.35) | CES2CES1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18994335 | 0.92 | CES2 (0.37) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL22013333 | 0.92 | CES2 (0.37) | CES2CES1SMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL9042000 | 0.90 | CES2 (0.33) | CES2CES1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL428708 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | MERCK PATENT GMBH (DE) | 2018-07-10 | — | — | US | claimed |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2017-05-18 | — | — | US | claimed |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2014-06-12 | — | — | US | claimed |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| CN-119562945-A | IKK inhibitors | 癌症研究技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250059200-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119487006-A | Amide compounds as PGE2 receptor antagonists | 广东新契生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2001023380-A1 | PIPERIDINE DERIVATIVES AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0982304-A1 | Piperidine derivatives having effects on serotonin related systems | ELI LILLY AND COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000000203-A1 | AZEPINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-2000000198-A1 | PIPERIDINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-2000000196-A1 | PYRROLIDINE AND PYRROLINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999031077-A1 | ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR | ELI LILLY AND COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0924205-A1 | Arylpiperazines having activity at the serotonin 1a receptor | ELI LILLY AND COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1993014086-A1 | SUBSTITUTED 1-ISOQUINOLONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS | SYNTEX (U.S.A.) INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| US-4927963-A | Novel processes for the synthesis of certain bicyclo(4.2.0)octane derivatives with valuable therapeutic properties | SYNTEX (U.S.A.) INC. (US) | 1990-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059200-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | GGH, GEMIN4, GMNN | CES2 767/4885CES1 963/4885SMN1; SMN2 3895/4885 |
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | CES2 4870/4885CES1 1997/4885SMN1; SMN2 3836/4885 |
| US-10016448-B2 | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity | BTK, SYK, LCK | CES2 4289/4885CES1 3108/4885SMN1; SMN2 4722/4885 |
| US-20250161304-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | CES2 3341/4885CES1 2599/4885SMN1; SMN2 4593/4885 |
| US-20140162983-A1 | Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | CES2 4289/4885CES1 3108/4885SMN1; SMN2 4722/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | CES2 3131/4885CES1 2029/4885SMN1; SMN2 2828/4885 |
| US-20170136048-A1 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | BTK, SYK, LCK | CES2 4289/4885CES1 3108/4885SMN1; SMN2 4722/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | CES2 4687/4885CES1 4238/4885SMN1; SMN2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.